New immunomodulating drugs in autoimmune blistering diseases.
The autoimmune blistering diseases are a fascinating group of diseases characterized by the presence of blisters involving the skin and mucous membranes. Understanding of the diagnosis, pathophysiology, and advances in treatment of these diseases has grown enormously in recent years. In this article, the author discusses the major clinical and immunopathologic findings in bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, linea IgA bullous disease, and pemphigus. The article focuses on the therapeutic management of patients with autoimmune blistering diseases, including the appropriate treatment of patients, with particular emphasis on the use of immunomodulating and immunosuppresive agents.
Korman
N J
NJ
Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D016107:Epidermolysis Bullosa Acquisita / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010390:Pemphigoid, Benign Mucous Membrane / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D010391:Pemphigoid, Bullous / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D010392:Pemphigus / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D012867:Skin / Q000276:immunology; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D007070:Immunoglobulin A; D007166:Immunosuppressive Agents